Preclinical animal trials conducted through Michigan Medicine's research programme found that a gut-focused compound under investigation was able to reverse the progression of an advanced form of non-alcoholic fatty liver disease — a pathway researchers had not previously associated with the condition. Labelled DT-109, the compound targets harmful gut bacteria, reinforces the intestinal lining, and blocks inflammatory substances before they can travel through to the liver.
Published in The Journal of Clinical Investigation, the research demonstrated that the method reversed metabolic dysfunction-associated steatohepatitis (MASH) in animal subjects, pointing toward a treatment avenue for a condition that has long resisted straightforward clinical management.
Roughly one in fourteen people globally live with MASH. Fat deposits building up inside liver tissue set off an inflammatory response and begin breaking down cells, marking this condition as an advanced stage of fatty liver disease. Left untreated or unmanaged, the condition may advance toward cirrhosis — a state of widespread liver scarring — and from there toward liver cancer or outright liver failure.
Therapeutic options for the condition have expanded over recent years, yet the range of viable treatments remains narrow — a gap that researcher Eugene Chen, M.D., Ph.D., addressed by pointing to trial data showing DT-109 shields the intestinal epithelial barrier, thereby reducing the flow of damaging microbial byproducts into the bloodstream that are believed to drive both the onset and advancement of MASH.
Prior animal-model work by Chen's team had already established that DT-109 — a tripeptide built from glycine — held promise for addressing MASH, while the lead researcher, holding the Frederick G. L. Huetwell Professorship of Cardiovascular Medicine at the University of Michigan Medical School, noted that the compound appeared to offer benefits to the gastrointestinal tract and warranted further investigation as a potential MASH therapy. Composed of three linked amino acids — the fundamental units from which proteins are assembled — a tripeptide ranks among the smallest molecular structures in biochemistry.
Findings from the study trace a pathway in which shifts in the microbial population of the gut trigger a sequence of events that progressively harms the liver, while also showing how DT-109 can block that sequence before damage takes hold. Elevated levels of Clostridium perfringens — a gut bacterium that releases ammonia during digestion — had already been identified by the researchers as a factor in MASH development, a finding they established ahead of any testing on the drug itself.
Elevated ammonia concentrations can irritate and wear away the gut's inner protective layer. Under typical conditions, this lining along the digestive tract acts as a barrier that keeps potentially harmful substances from crossing into the bloodstream. Microbial byproducts and harmful substances gain a pathway to the liver once that intestinal barrier begins to break down. Settling there, these particles can set off inflammatory responses and alter immune activity in ways that compound harm to the liver.
Among the immune responses documented is an overactivation of CD8+ T cells — white blood cells whose ordinary function is to seek out and eliminate cells that have been infected or have turned abnormal. When these cells lose proper regulation and begin firing at higher-than-normal rates, the resulting activity feeds into inflammatory pathways linked to MASH progression.
Laboratory testing across multiple experimental rounds revealed that DT-109 interferes with this harmful feedback loop by conditioning the intestinal environment and bolstering the mucosal lining that shields the gut. Across test populations spanning mice and nonhuman primates alike, the compound drove down concentrations of Clostridium perfringens while reducing the volume of ammonia generated within the gut. Those adjustments reinforced the gut lining and reduced the passage of microbial byproducts into the bloodstream, lowering the risk of liver harm.
Nonhuman primates yielded the most favourable data, a finding attributed in part to how closely their hepatic function and gut microbial populations mirror the corresponding systems in humans rather than in rodents. In those animal subjects, the compound DT-109 reduced hepatic inflammation while also lowering the severity with which MASH presented. Jifeng Zhang explained that the drug works by tying microbiota regulation to liver defence — restoring the gut barrier so that ammonia and other pro-inflammatory microbial byproducts are kept from migrating systemically through the gut-liver axis.
The gut-liver axis describes the tight biological connection linking the digestive tract to the liver, and the research team noted that DT-109 operates mainly within the gastrointestinal tract while its effects extend beyond that region. Blood flowing toward the liver travels through the intestinal wall and its draining vessels before reaching that organ, a route that ties hepatic condition directly to the composition of gut microbial communities and the structural integrity of the intestinal lining.
The intestinal barrier's protective function — an area where the compound has shown promise — positions it as a potential avenue for addressing other disorders tied to inflammation and metabolic disruption, according to researchers. Earlier animal trials involving nonhuman primates indicated that DT-109 holds back the buildup of atherosclerotic plaques while also reducing arterial calcification. Fatty deposits and other matter that build up along the inner surfaces of artery walls form what are known as atherosclerotic plaques, which can narrow the passage through which blood travels and raise a person's likelihood of developing cardiovascular complications. When calcium accumulates along the inner walls of blood vessels, those vessels gradually lose their natural elasticity — a process tied to the development of cardiovascular disease.
Beyond potential applications elsewhere, the team has turned its attention to whether the same compound might offer relief for people living with inflammatory bowel disease — an umbrella term covering chronic gut conditions such as Crohn's disease and ulcerative colitis. Whether DT-109 proves effective against those conditions remains a question that further study will need to address.
Trial data aside, DT-109 remains at an experimental stage with no transition to broader application yet recorded. Reversing MASH in animal models has been demonstrated within the trial's scope, yet whether it can deliver comparable outcomes in people — without posing unacceptable risks — remains an open question for researchers.
Researchers plan to subject the compound to additional evaluation in the next phase of work, with advancement toward clinical trials as the stated aim. Elliot Tapper, M.D., Academic Director of Hepatology at Michigan Medicine, noted that the study offers new evidence on how MASH develops and points toward a treatment path for a condition that has long proved difficult to manage, adding that patients with MASH require a therapy that is both safe and effective and capable of supporting liver and heart health.
Ying Zhao, Oren Rom, Jifeng Zhang, and Y. Eugene Chen are named as inventors on a patent application covering tripeptides and the treatment of metabolic, cardiovascular, and inflammatory disorders. Named among the inventors behind DT-109, Chen holds a listed patent contribution to the compound. Patent ownership for the compound rests with the University of Michigan, which has since entered into a licensing arrangement with Diapin Therapeutics covering its commercial use. Diapin — a company in which both Chen and the university hold equity stakes — provided DT-109 for the study and continues to advance the compound toward further development.
